Cargando…
PBK/TOPK Is a Favorable Prognostic Biomarker Correlated with Antitumor Immunity in Colon Cancers
Immune checkpoint inhibitor therapy has proven efficacy in a subset of colon cancer patients featuring a deficient DNA mismatch repair system or a high microsatellite instability profile. However, there is high demand for more effective biomarkers to expand the colon cancer population responding to...
Autores principales: | Lee, Dong-Hee, Jeong, Yu-Jeong, Won, Ju-Young, Sim, Hye-In, Park, Yoon, Jin, Hyung-Seung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869639/ https://www.ncbi.nlm.nih.gov/pubmed/35203508 http://dx.doi.org/10.3390/biomedicines10020299 |
Ejemplares similares
-
PBK/TOPK Inhibitor Suppresses the Progression of Prolactinomas
por: Zhu, Kejing, et al.
Publicado: (2022) -
PBK/TOPK Expression Predicts Prognosis in Oral Cancer
por: Chang, Chin-Fang, et al.
Publicado: (2016) -
PBK/TOPK: A Therapeutic Target Worthy of Attention
por: Han, Ziping, et al.
Publicado: (2021) -
PBK/TOPK: An Effective Drug Target with Diverse Therapeutic Potential
por: Huang, Hai, et al.
Publicado: (2021) -
PBK/TOPK mediates geranylgeranylation signaling for breast cancer cell proliferation
por: Dou, Xiaoyan, et al.
Publicado: (2015)